Trimeris to axe R&D ops in '08 restructuring

The axe is dropping on Trimeris' R&D operations. The North Carolina biotech says it will eliminate R&D next year, once an early-stage trial for its experimental HIV drug is completed in the first half of the year. R&D staffers have been advancing TRI-1144, the company's new fusion inhibitor. The move is expected to cut its costs from the $21 million to $23 million mark in 2007 down to $10 million to $14 million.

"While market conditions and the significant risks involved in research and development have required the company to shift strategic direction, Trimeris still possesses significant financial assets that include substantial cash and revenue streams from the sale of Fuzeon in collaboration with Roche," said Trimeris Chief Executive Martin Mattingly.

- check out the release from Trimeris
- here's the AP report for more info

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.